TNFRSF1B and graft versus host disease: In conclusion, these data point to the fact that TNFR2 is a promising targetable molecule for the expansion of donor or recipient Tregs that display functional suppressive activity to modulate the course of GvHD across distinct histocompatibility barriers and to mitigate the process of chronic rejection of vascularized allografts.